<DOC>
	<DOCNO>NCT01761227</DOCNO>
	<brief_summary>Purpose : The purpose study examine efficacy safety Fufangdanshen Tablets patient mild moderate vascular dementia ( VaD ) .</brief_summary>
	<brief_title>Efficacy Safety Fufangdanshen Tablets Mild Moderate Vascular Dementia</brief_title>
	<detailed_description>This multicenter , double-blind , placebo-controlled study evaluate safety effectiveness Fufangdanshen Tablets patient vascular dementia . All patient initially receive placebo 2 week period receive Fufangdanshen Tablets placebo 6 month . The primary measure effectiveness include change baseline end treatment ADAS-cog/11 score ( Alzheimer 's Disease Assessment Scale : sum 11 cognitive item ) CIBIC-plus score ( Clinician 's Interview Based Impression Change - Plus Caregiver Input ) . Additional measure effectiveness include change baseline end treatment MMSE score ( Mini-mental State Examination ) , ADL ( Ability Daily Living ) score . Safety evaluation ( incidence adverse event , electrocardiogram ( ECGs ) , physical examination , laboratory test ) perform throughout study . Patients complete double-blind portion study follow 12 week . Effectiveness assess 12 week , 24weeks 36 week . Safety evaluation ( incidence adverse event , ECGs , physical examination , laboratory test ) perform 12 week , 24weeks 36 week study . The study hypothesis Fufangdanshen Tablets effective treatment patient vascular dementia well tolerate . Double-blind : Fufangdanshen Tablets : 3 tablet per time , 3 time per day , placebo : 3 tablet per time , 3 time per day . The placebo similar smile appearance Fufangdanshen Tablets .</detailed_description>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<criteria>Inpatients outpatient meet diagnostic criterion probable VaD establish accord Diagnostic Statistical Manual Mental Disorders ( fourth edition ) （DSMⅣ） National Institute Neurological Disorders Stroke Association Internationale pour la Recherche et l'Enseignement en Neurosciences ( NINDSAIREN ) eligible participate . Weighing 45 90 kg ; The diagnosis also compatible finding recent ( within last 12 month ) magnetic resonance image ( MRI ) brain The Hachinski Ischemia Scale ( HIS ) score＞4 . six month ' mild moderate VaD duration inclusion . Mildtomoderate dementia ( Score MiniMental State Examination ( MMSE ) define 11 26 ) The Hamilton Depression Scale ( HAMD 17 item ) score ≤ 12 consistent informant accompany schedule visit Ability read , write , communicate , understand cognitive testing instruction Neurodegenerative disorder Parkinson 's disease , AD secondary type dementia ; cognitive impairment result condition acute cerebral trauma , cerebral damage due lack oxygen , vitamin deficiency , infection meningitis AIDS , significant endocrine metabolic disease , mental retardation , brain tumor significant psychiatric disease , active peptic ulcer , clinically significant liver , kidney lung disorder , heart disease history epilepsy , convulsion , drug abuse alcohol abuse history hypersensitivity treatment drug ; concomitant drug potential interfere cognition ; administration investigational drug ; female child bear potential without adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Vascular dementia</keyword>
	<keyword>Fufangdanshen Tablets</keyword>
	<keyword>Randomized Controlled trial</keyword>
	<keyword>Chinese Medicine</keyword>
</DOC>